BMJ Open Effectiveness and cost-effectiveness of TeleStroke consultations to support the care of patients who had a stroke presenting to regional emergency departments in Western Australia: an economic evaluation case study protocol

Christina Tsou ¹, Suzanne Robinson ¹, James Boyd,² Shruthi Kamath,³ Justin Yeung,³ Stephanie Waters,³ Karen Gifford,³ Andrew Jamieson,³ Delia Hendrie ¹

To cite: Tsou C, Robinson S, Boyd J, *et al.* Effectiveness and cost-effectiveness of TeleStroke consultations to support the care of patients who had a stroke presenting to regional emergency departments in Western Australia: an economic evaluation case study protocol. *BMJ Open* 2021;**11**:e043836. doi:10.1136/bmjopen-2020-043836

► Prepublication history is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-043836>).

Received 14 August 2020
Revised 14 December 2020
Accepted 18 December 2020

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Christina Tsou;
christina.tsou@curtin.edu.au

ABSTRACT

Introduction The Western Australia (WA) Acute TeleStroke Programme commenced incrementally across regional WA during 2016–2017. Since the introduction of the TeleStroke Programme, there has been monitoring of service outputs, including regional patient access to tertiary stroke specialist advice and reperfusion treatment; however, the impact of consultation with a stroke specialist via telehealth (videoconferencing or telephone) on the effectiveness and cost-effectiveness of stroke care and the drivers of cost-effectiveness has not been systematically evaluated.

Methods and analysis The aim of the case study was to examine the impact of consultation with a stroke specialist via telehealth on the effectiveness and cost-effectiveness of stroke and transient ischaemic attack care using a mixed methods approach. A categorical decision tree model will be constructed in collaboration with clinicians and programme managers. A before and after comparison using state-wide administrative datasets will be used to run the base model. If sample size and statistical power permits, the cases and comparators will be matched by stroke type and presence of CT scan at the initial site of presentation, age category and presenting hospital. The drivers of cost-effectiveness will be explored through stakeholder interviews. Data from the qualitative analysis will be cross-referenced with trends emerging from the quantitative dataset and used to guide the factors to be involved in subgroup and sensitivity analysis.

Ethics and dissemination Ethics approval for this case study has been granted from the Western Australian Country Health Service Human Research and Ethics Committee (RGS3076). Reciprocal approval has been granted from Curtin University Human Research Ethics Office (HRE2019-0740). Findings will be disseminated publicly through conference presentation and peer-review publications. Interim findings will be released as internal reports to inform the service development.

Strengths and limitations of this study

- Comparison of the impact of stroke specialist consultation via telehealth in regional Australia in supporting the management of different stroke subtypes.
- The decision tree model will be constructed in collaboration with clinicians and programme administrators directly involved in the delivery of the TeleStroke Programme.
- Use of local administrative data as model inputs enables the base model to reflect the reality of the regional Western Australia (WA) Health service delivery.
- Collaboration with WA Health stakeholders involved in TeleStroke Programme design and implementation to optimise utility of the case study to inform service development and expansion.
- Conversion of the functional outcome Modified Rankin Scale score to quality-adjusted life years relies on national or international averages.

INTRODUCTION

Advances have been made in acute stroke management in recent years, enabling patients who had an ischaemic stroke to experience significant improved function and recovery poststroke.¹ The Western Australia (WA) Acute TeleStroke Programme commenced incrementally across regional WA during 2016–2017. Since commencement, the number of WA rural patients undergoing stroke reperfusion treatment that is mechanical thrombectomy (MT) and/or thrombolysis has increased across regional WA. Since the introduction of the TeleStroke Programme, there has been monitoring

of service outputs, including regional patient access to tertiary stroke specialist advice and reperfusion treatment; however, the impact of consultation with a stroke specialist via telehealth on the effectiveness and cost-effectiveness and the drivers of cost-effectiveness has not been systematically studied.

The current body of knowledge on the effectiveness and cost-effectiveness of the telestroke services in rural and remote emergency departments (EDs) focuses on acute ischaemic stroke and the impact of telestroke on timely administration of thrombolysis and associated hospital resource use, including interhospital transfers avoided. The studies have found telestroke to improve accuracy in decision making compared with telephone² and to increase safe local administration of thrombolysis³ with similar results to patients presenting directly to the tertiary stroke centres.⁴ However, patients who had moderate to severe ischaemic stroke treated with thrombolysis may potentially benefit from care at a tertiary stroke centre.⁵ Hence, local thrombolysis administration does not completely mitigate the need for tertiary centre care. In addition, the increased accuracy in decision making also means that patients presenting to rural hospitals with more severe stroke (large vessel occlusion) who later transfer to tertiary hospitals can have equitable outcomes to patients who presented directly to the tertiary centre.⁶ Effectiveness studies typically focus on patients who had an ischaemic stroke. The pattern and impact of telestroke access to haemorrhagic stroke, transient ischaemic attacks (TIAs) and stroke mimics from ED presentation to discharge is not well documented in the literature.⁷

Medeiros De Bustos *et al* have recently observed that majority of telestroke studies concern acute management.⁸ There have been few socioeconomic studies to determine the true impact of telestroke in medical and economic terms.⁸ There is also much to add to the literature on the association of patient outcome at discharge and in the longer term for each stroke subtypes to health systems cost.

Despite Whetten *et al* and Demaerschalk *et al* estimating telestroke access to be the dominant strategy compared with no access, the results are only valid when a long list of assumptions hold true.^{7,9} Cost-effectiveness analyses of rural and remote telestroke programmes, to date, have used effectiveness measures from previous clinical trials adjusted to a specific setting (eg, ED), based on resource use data obtained from published literature or publicly available data.^{7–11} These studies make assumptions or estimates from multiple data sources or rely on clinical expert opinions on activity variables, such as probability of transfer to tertiary centres, discharge destination and key resource use variables, such as cost of telestroke equipments.^{10,11} These economic models have not taken into account haemorrhagic stroke or patients who had a TIA who may benefit from telestroke,¹⁰ and did not consider secondary benefits of acute telestroke access on resource use required within a subacute episode of care following stroke and TIA.¹¹

This study uses the TeleStroke Programme in WA as a case study to examine the effectiveness and cost-effectiveness of telehealth to support the care of patients presenting to regional EDs in WA. The primary interest in this research is twofold: first, to understand the effectiveness and cost-effectiveness of the TeleStroke based on its current operation and, second, to gain insight into the drivers of cost-effectiveness of the service to inform future expansion of the TeleStroke Programme. The following research questions will be addressed:

1. Is seeing a stroke specialist via telehealth more effective and cost-effective than no stroke specialist involvement for patients presenting to rural and remote hospitals?
2. What are the drivers of cost-effectiveness in the aforementioned scenarios?
3. What factors other than access to stroke specialists via telehealth affect the clinical outcomes for patients presenting to a Western Australian Country Health Service (WACHS) site with and without access to CT?
4. What is the acceptability of stroke specialist consultation via telehealth to health professionals and health consumers and how do the enablers and barriers to its implementation help to explain the findings from the cost-effectiveness analysis?

METHODS AND ANALYSIS

A mixed methods methodology will be used to allow incorporation of healthcare complexities into a systematic understanding of the factors that influence health service provision.¹² A mixed methods approach is frequently used in health services research to allow quantitative data from survey and administrative records to combine with contextual information from qualitative data collections to support a better-informed decision about health service delivery. Guided by the model for assessment of telehealth (MAST),¹³ this case study will use a sequential explanatory design,¹⁴ with a combination of the methods described further; that is, the case study will commence with an economic evaluation of the TeleStroke Programme (quantitative phase) then conduct an analysis of its implementation, which will be guided by a modified Consolidated Framework for Implementation Research (mCFIR) (qualitative phase), followed by the combined interpretation of the findings from the two phases of analysis to understand the drivers of cost-effectiveness.

The WA Acute TeleStroke Programme industry stakeholders have been engaged in the design of the economic evaluation to incorporate current process of care into the case study to ensure the outcomes measured in this study are meaningful to future development of the programme. A quantitative assessment will be conducted on the effectiveness of stroke specialist consultation via telehealth on alignment to clinical protocols to achieve desirable clinical outcome, improved functional outcome for patients and the impact of consultation with a TeleStroke specialist on the diagnosis of stroke. Descriptive output from this

analysis will also provide model input into the economic model.

A decision tree analytical model will be built to inform the calculation of the incremental cost-effectiveness ratio (ICER) for the three types of stroke presentations: haemorrhagic stroke, acute ischaemic infarction and TIA when a TeleStroke specialist consultation has taken place. Complementing this information will be a novel qualitative data collection from relevant clinicians, health professionals, and policy makers to understand factors associated with implementation of the TeleStroke Programme across WACHS facilities. In the explanatory phase, knowledge generated from the various parts of the research will be triangulated to help interpret the results and the effectiveness and cost-effectiveness analysis. This process will also contribute to improving the process of service delivery. [Figure 1](#) presents a schematic diagram of the study methodology for the WA Acute TeleStroke case study.

Case study settings

Medical emergencies in rural and remote WA typically present to one of the WACHS facilities covering 2.5 million square kilometres. There are 12 sites across WACHS with CT capabilities (CT sites) and 108 non-CT sites, including 15 district health services (DHSs), 49 small hospitals, 24 nursing posts/health centres and 20 Aboriginal community clinics. Three geographically defined regional-metropolitan stroke pathways have been endorsed in WA linking WACHS facilities with partnered metropolitan acute stroke units. All WACHS emergency medical services are evaluated against the Emergency Care Capability Framework (ECCF) as the minimum requirements for role delineation capability and the minimum requirements to support the service.

Administrative data collections

Six of the 12 CT sites across WACHS currently upload data to the WA Acute Stroke Data Collection (WAASDC). In this exploratory economic analysis, only sites contributing data to the WAASDC will be included. Learnings from this analysis will inform future economic evaluation

designs across all WACHS sites. The WAASDC is a local file audit of stroke-related indicators, including whether a TeleStroke specialist was consulted. Other process-related indicators are available from the WACHS emergency department data collection (EDDC) and for admitted patients from the hospital morbidity data collection (HMDC), which are both routinely collected administrative datasets. By linking the three data sets, patients' journey between WACHS hospitals will be studied.

To understand the patients' journey to tertiary/quaternary care at other large or metropolitan sites, linkage to tertiary centre ED and admitted datasets will be done using patient identifier and date and time of discharge from WACHS hospital. The patient unique identifier will also be used to extract time and date of death from the state's mortality data collection.

Stroke case identification in the clinical process: an International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) analysis

All stroke cases will be followed up from the time of presentation to ED to the point of discharge from hospital. In-hospital stroke of admitted patients or admitted patients bypassing the ED will also be included in this analysis.

Stroke or TIA cases from the HMDC will be traced back to the EDDC to identify the principal diagnosis at ED. A separate stroke care audit was conducted on patients with established stroke or TIA diagnosis in the WAASDC. Patients identified as stroke or TIA cases in the EDDC but who were either discharged home or transferred to a tertiary centre for further treatment will be included as stroke cases. Those undergoing consultation by a TeleStroke specialist after 1 January 2017 will be identified as cases and those presenting before 1 January 2016 are comparators. A 12-month window period is to allow for data stabilisation. Descriptive analysis will then be performed on the cases and comparator subsets to provide model inputs to the cost-effectiveness analysis.

A subset of patients who have a stroke or TIA diagnosis recorded in the HMDC with a non-stroke/TIA diagnosis in EDDC will be extracted for analysis with presenting symptoms and whether consultations with TeleStroke specialists took place. This will give an understanding of the impact of TeleStroke on the diagnosis of stroke in the hospital journey of patients who had a stroke. The proportion of each type of change in diagnosis from EDDC to HMDC will be calculated and compared between the cases and comparator groups. This subset of patients will also be included as stroke cases for this analysis.

Cost-effectiveness analysis

[Figure 2](#) summarises the components of the WA Acute TeleStroke case study. This study will use a decision tree analytical model to examine the incremental cost-effectiveness comparing the acute stroke care supported by TeleStroke consultations to acute stroke care prior to the implementation of the Acute TeleStroke Programme.

Figure 1 Western Australia Country Health Service Acute TeleStroke case study methodology. mCFIR, modified Consolidated Framework for Implementation Research.

What are we studying?

Figure 2 Components of the WA acute telestroke case study. ICER, incremental cost-effectiveness ratio; mRS, Modified Rankin Scale; QALY, quality of life years; WA, Western Australia.

The ICER will be calculated to determine the cost of increasing mRS by one unit, and another set of ICERs for cost per quality-adjusted life year (QALY). Subgroup and sensitivity analysis will be performed to understand the drivers of cost-effectiveness and interpreted together with the qualitative data collection in the triangulation phase.

Time horizon

There are three critical points in time for outcome determination in this study. First, preintervention mRS to capture the functional status before thrombolysis or MT. Second, at discharge, and finally at 90–180 days postdischarge. The overall effectiveness of the stroke specialist telehealth consultations is determined by examining the change in functional status between pre-intervention and 90–180 days postdischarge. The functional status at discharge is significant in examining whether the patient returned to the same functional state prior to the index stroke by comparing with premorbid mRS.

The WA Acute stroke pathways aligning the seven WACHS regions to tertiary hospitals commenced on 1 January 2016. Patients presenting to WACHS ED from this point onwards can receive consultation from TeleStroke specialists. To allow a 12-month time window for data stabilisation, TeleStroke case selection will commence 12 months after the relevant site commences uploading to the WAASDC. The comparator selection will be from December 2015 to the earliest available records for the ED and HMDC data collections. This time horizon will be related to both the cost and effectiveness data collection.

Study perspectives

The analysis in this study will take the WACHS and WA public health systems perspectives by combining Country WA and metropolitan public hospital service uses, including TeleStroke Services, stroke unit care and neurological interventions.

Intervention and comparator

The study intervention in this study is stroke specialist consultation via telehealth. This is one component of the overall TeleStroke Programme. Given that TeleStroke consultations have been embedded within clinical workflows and processes, a contemporaneous non-TeleStroke comparator group within hospital sites in this study would be subjected to selection bias with more TeleStroke use in higher acuity presentations. This, in addition to the vast geographical and community variations across WACHS regions, makes a contemporaneous comparator for the case study sites not feasible. Therefore, prestudy and post-study designs are appropriate.

Index presentation and stroke case identification

Index presentations will be identified using the principal discharge diagnosis (ICD-10) from the WACHS ED and all diagnosis fields from the admitted data collections. Table 1 shortlists the International Statistical Classification of Diseases and Related Health Problems codes to be used to identify stroke presentations. Activity-level model input to reflect care pathway will be collected from multiple data sources, including the EDDC and HMDC and the WAASDC. Model inputs from the local data collections will be supplemented by the probability from the Australian Stroke Clinical Registry (AuSCR) or international averages published in peer reviewed literature to complete model inputs.

Decision model development

A categorical decision tree model will be developed in collaboration with WACHS clinicians and programme administrators capturing probabilities and decisions from WACHS ED presentation to the point of discharge from hospital. The modified Rankin Scale (mRS) score at discharge will be the final outcome in the decision tree model. Time critical clinical outcomes (see Outcome

Table 1 Stroke and TIA ICD-10-AM subclassifications

Disease	Subcategory (ICD-10-AM subclassifications)	ICD-10-AM
Stroke	Intracerebral haemorrhage	I61.0–I61.6, I61.8–I61.9
	Other non-traumatic intracranial haemorrhage	I62.9
	Cerebral infarction	I63.0–I63.6, I63.8–I63.9
	Stroke, not specified as haemorrhage or infarction	I64
TIA	Transient cerebral ischaemic attacks, unspecified	G45.9

ICD-10-AM, International Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification; TIA, transient ischaemic attack.

determination section) will be used in a sensitivity analysis in the assessment of drivers of cost-effectiveness. Transition probabilities from presentation to a WACHS ED to discharge will come from the WACHS administrative datasets. The decision tree will be constructed by asking the following questions:

- ▶ Did a TeleStroke consult take place?
- ▶ Was there a bleed into the brain? (haemorrhagic vs non-haemorrhagic stroke).
- ▶ Was a major cerebral blood vessel blocked, that is, large vessel occlusion?
- ▶ Was the blood clot removed? (MT vs no MT).
- ▶ Was treatment given to break up the blood clots? (thrombolysis vs no thrombolysis).
- ▶ Did transfer to a tertiary centre take place? (transferred vs admitted locally or managed locally).
- ▶ Were there complications associated with the treatment? (intracerebral haemorrhage (ICH) vs no ICH).
- ▶ What was the functional status of the patient on discharge and 90–180 days postdischarge? (mRS scores 0–2 vs 3–5 vs 6).

Identification, measurement and valuation of resource use

Cost model calculations will be based on WA Health service and resource use relating to the initial hospital presentation for stroke or TIA from presentation to hospital discharge, and from hospital discharge to 90–180 hours posthospital discharge. Table 2 summarises the cost items.

Measuring resource use

Service cost will be collected from the WA Health costing system. The resource use will be built around individual patient encounters for the WACHS activity-based sites; these are the regional resource centres (RRCs) and the DHSs. All CT sites are either situated within a RRC or DHS; therefore, it is possible to build cost around individual patient encounters. Using the encounter identifier will allow integration of component direct healthcare costs supporting the episode of service delivery and can

Table 2 Cost items for the WACHS acute telestroke case study

Perspectives	Health systems perspective	
	WACHS	WA Health
Capital costs	IT equipment	IT equipment
Programme set-up cost	WACHS acute stroke programme costs	Western Australia Stroke Services Project costs
Direct healthcare costs	ED service delivery cost	ED service delivery cost
	Hospital admission and rehabilitation cost (include all direct patient care plus overheads comprising hospital, region and central office)	Hospitalisation admission and rehabilitation cost (include all direct patient care plus overheads)
Direct non-healthcare costs (overhead costs)	Overheads comprising hospital, region and central office	Hospital overheads

ED, emergency department; IT, information technology; WA, Western Australia; WACHS, Western Australian Country Health Service.

potentially identify the breakdown of costs associated with the encounter, including inpatient admissions, theatre and diagnostics services.

Valuing resource use

Unit cost data are available up to the 2018–2019 financial year and all monetary values will be expressed in Australian dollars. All costs will be adjusted to mid-2018 value.

TeleStroke Programme costs will be evenly spread over the years since commencement of the WA Acute TeleStroke Programme. These include funding for tertiary specialists, project support and data collection through the Western Australia Stroke Services Project. It will not be meaningful to apply an annual discount for programme costs as only 2 years of programme cost will be collected. Information and communication technologies (ICT) equipment costs will be depreciated on a straight line over their estimated useful lives.

Outcome determination

Time-sensitive measures

Stroke care is time sensitive; hence, several time-sensitive measures will be used to reflect the effectiveness of stroke protocol implementation with potential impact on patient outcome. Time-sensitive measures showing strong association to functional outcomes for patients who had a stroke will be identified as time-critical clinical effectiveness measures and will be used as a surrogate clinical outcome measure.

Door to imaging time indicates adherence to stroke care protocol, and door to first medical or nursing

review, and door to TeleStroke consultation can impact patient outcome; while the length of hospital stay can reflect patient outcome and also goes directly to resource use. Onset to imaging time and onset to first medical or nursing review are the more clinically significant indicators; however, time of onset may not be accurately determined, and it is expected that the time from onset analysis will be performed on a smaller subset of samples. Timely administration of thrombolysis to patients with ischaemic stroke is another significant factor impacting on patient outcome. This will be incorporated into the analysis if there is sufficient sample size for effectiveness analysis.

Clinical interventions in haemorrhagic stroke are control of blood pressure and hemicraniectomy. Hemicraniectomy in WA will require transfer to a tertiary centre. Shorter door to tertiary centre transfer will be a meaningful time-critical clinical effectiveness measure. This will need to be interpreted in tandem with (regional ED) door to (tertiary centre) hemicraniectomy time to incorporate variations in transfer time (time transfer out of regional hospitals to arrival time at tertiary centre), and tertiary centre care.

Functional outcome measure

This study will use the mRS score as the main functional outcome measure. An mRS score of 1–2 is considered a good functional outcome from stroke^{5,9}; an mRS score of 6 is death, while an mRS score of 3–5 indicates mild to severe disability/dependency requiring provision of carer support. This indicates costs occurring outside of hospital system, including inability to be employed and loss of productivity to society. Table 3 provides descriptions for the mRS scores.

The mRS score at discharge for patients presenting to WACHS ED prior to January 2020 will be retrospectively determined from discharge summary audits independently conducted by the WACHS Rural TeleStroke Neurology Fellow and WACHS TeleStroke Programme Manager and WACHS TeleStroke Programme Research

Support Officer, who will discuss any discrepancies in scores to reach a consensus score. Similarly, the 90–180 hours of mRS scores for patients presenting to WACHS ED prior to January 2020 will be determined from subsequent public hospital use audits.

The discharge destination rule in Nelson *et al*¹⁰ will not be followed in this case study because anecdotal observation of WACHS patients indicate that patients who are discharged to residential aged care facility (RACF) are more likely to stay the same or deteriorate, while patient discharge home may improve with further rehabilitation. Nelson *et al*¹⁰ applies the following rules to determine the 90–180 hour of mRS score for patients who have not been readmitted to the public hospital system postdischarge from index episode. The initial mRS score was assumed to improve by 1 point at 90 days for patients who were discharged from the hospital to rehabilitation in the community. The initial mRS score was assumed to not change in patients who were discharged either home or to RACF.¹⁰ Across WACHS, if a patient is discharged to rehabilitation, majority in outpatient services, they may have improvement in mRS at 90–180 days. If the rehabilitation is provided by WA Health, mRS may be extracted from the patient's medical record. For patients who have no further health system intervention postdischarge, this study assumes that their mRS remains unchanged; however, there is also the possibility that they access non-WA Health rehabilitation and mRS improves. Deterioration may be marked by subsequent WA Health hospital admission.

QALY estimation

This study will use the 90–180 hours of mRS score to estimate QALYs gained for the aforementioned TeleStroke scenarios.^{7,9,10} QALY will be calculated using years of life remaining for each mRS at 6 months multiplied by utility weight sourced from CEA registry and their resulting sources.^{7,15–17} The years of life remaining will be sourced from WACHS administrative data collections supplemented by national averages from AuSCR or previous studies.¹⁸ Utility weights will be measured on a 0–1 scale where 1 represents a state of perfect health and 0 represents death.

Estimated sample size

The Glick sample size formula¹⁹ has been used to estimate the sample size required for each of the TeleStroke and non-TeleStroke groups for this study to have 95% confidence with 80% study power. It is assumed that both groups will have equivalent SD for cost and QALY, and equivalent sample sizes. The expected variations between the TeleStroke and non-TeleStroke groups have been sourced from previous cost-effectiveness analysis in the rural and remote context by Nelson *et al*¹⁰ and Whetten *et al*.⁷

Edney *et al* in 2017 calculated a reference willingness to pay of AU\$28 033 per QALY gained and suggested that new technologies with ICER above AU\$40 000 per

Table 3 Modified Rankin Scale score descriptions

Score	Description
0	No symptoms at all
1	No significant disability despite symptoms, able to carry out all usual duties and activities
2	Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
3	Moderate disability, require some help but able to walk without assistance
4	Moderate severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance
5	Severe disability; bedridden, incontinent and require constant nursing care and attention
6	Dead

QALY gained was recommended for public funding.²⁰ Assuming the WA sample has equivalent variations in average resource use and QALY gained between the TeleStroke and non-TeleStroke groups, 607 individuals presenting with acute stroke episodes is required for each of the TeleStroke and non-TeleStroke groups if the public sector's willingness to pay is AU\$28 033 per QALY gain. This estimate of sample size would be 482 individuals if this willingness to pay is AU\$40 000.

Analysis

Base case analysis and regression

Baseline characteristics and clinical and functional outcomes of the patients in the before TeleStroke and after TeleStroke groups will be summarised by stroke subtypes. Differences in resource use and costs between the two groups will be tested using two-sample t-test (or non-parametric equivalents) and χ^2 tests for continuous and categorical variables, respectively. The mean costs of resource use in each care pathways in the decision tree and the difference in costs between the two groups will be calculated with 95% CI.

Incremental cost-effectiveness

The primary comparison is between the TeleStroke and non-TeleStroke groups and an overall ICER will be calculated using the formulae below at hospital discharge and at 90–180 hours.

The first set of ICER will be calculated using the mRS as the effectiveness measure using the following:

$$\frac{\text{CostTeleStroke} - \text{CostnoTeleStroke}}{\text{mRSatdischargeinTeleStroke} - \text{mRSatdischargeinnoTeleStroke}}$$

The second set of ICER will be calculated using QALY as the main outcome measure using the following:

$$\frac{\text{CostTeleStroke} - \text{CostnoTeleStroke}}{\text{QALYTeleStroke} - \text{QALYnoTeleStroke}}$$

Subject to sufficient statistical power, a series of subgroup analyses will be performed to assess whether the cost and effectiveness association is dependent on a third variable. The initial list of subanalyses is as follows, and the final list will be guided by findings from the qualitative phase of the study:

1. Gender.
2. Establishment.
 - a. Busselton Health Campus.
 - b. Bunbury Health Campus.
 - c. Albany Health Campus.
 - d. Geraldton Hospital.
 - e. Kalgoorlie Health Campus.
 - f. Northam Hospital.
3. Recurrence: stroke recurrence categories.
 - a. First-ever stroke.
 - b. Recurrent stroke <255 days (Western Australian median time to first stroke recurrence from first-ever stroke).²¹
 - c. Recurrent stroke >255 days.
4. Rehabilitation post index presentation.

5. Patients who had a haemorrhagic stroke who underwent hemicraniectomy.
6. Changes in ECCF domain achievement.

The model results will provide estimates for the ICER considering health outcome and costs at discharge and at 90–180 days postdischarge. The results of the economic evaluation including the subgroup and sensitivity analyses will be presented in terms of point estimates, cost-effectiveness planes and cost-effectiveness acceptability curves.

The stroke subtypes will be compared on the basis of incremental net monetary benefits. The net monetary benefit of the stroke specialist telehealth consultations with or without CT scans will be calculated as the mean QALY multiplied by the acceptable threshold values for the QALY (add reference) minus the mean cost of the TeleStroke Programme and CT scans. The threshold value should be interpreted as the monetary value of a QALY.

Sensitivity analysis

Sensitivity analysis will be performed to identify changes to ICER under a range of conditions. One-way analysis will be performed initially on varying the following variables: changes in TeleStroke consultation rates, changes in door to image time, changes in thrombolysis and MT numbers, changes in rate of transfer to CT sites, and changes in other time-sensitive outcomes listed previously. The variables for inclusion in the multivariate sensitivity analysis will be decided based on findings from the semistructured interviews and preliminary quantitative analysis of the administrative datasets.

Implementation factors to inform future expansion of Acute TeleStroke Programme delivery in WA

A qualitative data collection is incorporated into the study design to provide a robust evidence base to support the interpretation of findings from the effectiveness and cost-effectiveness studies described previously. Guided by mCFIR, this data collection is expected to provide a subsidiary evidence base informing the future development and implementation of the WA Acute TeleStroke Programme across WACHS.

Modified Consolidated Framework for Implementation Research

The Consolidated Framework for Implementation Research (CFIR)^{22 23} has been chosen as the underpinning interpretative framework to guide the qualitative study (including design of interview protocol) and the final interpretation of the drivers of cost-effectiveness to adequately capture the complex nature of rural and remote health service delivery. As the focus of this research is on factors enabling and barring the successful integration of telehealth into clinical service implementation, the Finch *et al* theoretical constructs of normalisation process theory²⁴ will add the system integration dimension and theoretical content. Key concepts in the MAST domains of preceding consideration, safety,

patient perspectives, organisational, sociocultural, ethical and legal aspects¹³ will also be mapped to the aforementioned, ensuring coherence with the previous experience in telehealth evaluation. The resultant mCFIR constructs will provide the initial categories in the qualitative analysis and will be iteratively applied throughout the interpretive phase of the research.

Construction of interview guide

An interview guide has been developed based on the initial evaluation of the WA Acute TeleStroke Programme implementation and impact within WACHS. Different sets of questions have been developed for the staff in the WACHS central office involved in the WACHS wide planning and implementation of the programme, programme sites with and without established pathways for stroke care. The draft interview protocol was reviewed by three stroke coordinators and senior managers within the WACHS Innovation and Development directorate.

Participant recruitment and the interview process

The aim of the qualitative component of this study was to explore and explain the factors impacting implementation of clinical telehealth strategies in rural and remote WA and the extent of their integration into routine clinical service delivery. The initial WACHS staff participants (seed participants) will be clinicians and programme administrators who have been involved in the commencement and implementation of the WA Acute TeleStroke Programme. The seed participants include senior leaders and managers, regional stroke coordinators and the neurology registrar. A snowball sampling technique will be used to identify and recruit further clinicians and health consumers to participate in the study.

The semistructured interviews will be conversational, and the interview protocol is designed for use as a guide to ensure consistent coverage of topic areas. Instead of asking every participant the exact questions, the prompts under the main questions will be used as checklists to ensure relevant themes are covered in the dialogues. Small focus groups of less than three staff may be used instead of one-on-one interview when required to meet the constraints of participants' schedules.

The interviews will be audio-recorded and transcribed verbatim and managed in NVivo. While the open coding is performed, notes will be taken under the mCFIR domain and construct headings. Axial coding will then be performed to make interconnections between the emerging themes within each CFIR construct. These relationship will be pulled into a relational model of causal conditions, central phenomenon, context, intervening conditions, action/interaction strategies and consequences.²⁵ Selective coding will then be performed to connect the emerging themes to produce a discursive set of theoretical propositions on telehealth integration in clinical service delivery.²⁵ The simultaneous data collection and analysis process will continue until data saturation is reached for all relevant constructs in the mCFIR.

Drivers of cost-effectiveness and generation of deliberative dialogue

This case study will use two methods to gain insights into the drivers of cost-effectiveness. It will be an iterative process between the subgroup and sensitivity analyses part of the economic analysis, and the qualitative exploration. These two processes will commence as separate and concurrent parts in the case study. A constant comparison of early findings will take place where key themes emerging from the dialogues and interviews with key industry stakeholders, and health consumers is expected to offer explanation to the findings from the subgroup and sensitivity analyses. Any new categories or factors emerging from this constant comparison of findings will feed into the subgroup and sensitivity analyses as new subcategories or factors for consideration in assessing the level of confidence of the ICERs calculated (whether the cost-effectiveness finding is robust when certain factors vary individually or in combination).

The understanding of the drivers of cost-effectiveness will include tacit knowledge of clinician, practitioners and consumers through deliberative dialogues generated during the final explanatory phase, that is, the interpretive phase of the research. The deliberative dialogues generated in the interview and dissemination of early findings are likely to create an evaluative practice supporting the sharing of best practice and informing future rural and remote telehealth planning and policy in WA Health.

Patient and public involvement

A consumer representative was involved in the conceptualisation of this protocol.

Ethics and dissemination

Ethics approval for this case study has been granted from the WACHS Human Research and Ethics Committee (WACHS HREC Project Reference Number RGS3076). Reciprocal approval granted from Curtin University Human Research Ethics Office (approval number HRE2019-0740). Findings will be disseminated publicly through conference presentation and peer-review publications. Interim findings will be released as internal reports to inform the TeleStroke Programme development.

Author affiliations

¹School of Public Health, Curtin University, Bentley, Western Australia, Australia

²School of Psychology and Public Health, La Trobe University, Melbourne, Victoria, Australia

³Western Australia Country Health Service, Perth, Western Australia, Australia

Twitter Christina Tsou @tsouc011 and Suzanne Robinson @Robinsonsuz

Contributors CT drafted and provided the initial design of the study. She has also coordinated input from the authorship to bring the work to publication. DH and SR provided input on health systems and health economic methodology. JB provided input on statistics and data linkage. AJ provided high-level clinical practice perspective in the rural and remote Australia. SK contributed specialist neurology knowledge and provided significant input in the methodology related to clinical effectiveness measures. JY brings regional emergency medicine perspective to this project. SW and KG provided programme implementation perspective and made significant contribution to the design of the interview protocol. All authors reviewed the final manuscript and agreed to submit for publication.

Funding This research was initiated by the WA Country Health Services (WACHS), Curtin University, and received financial support from both institutions as well as the Digital Health Collaborative Research Centre in the form of Ph.D. scholarships. WACHS also contributed in-kind support in the form of clinician time, industry supervisors, administrative and research infrastructure support.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Christina Tsou <http://orcid.org/0000-0001-6780-8117>

Suzanne Robinson <http://orcid.org/0000-0001-5703-6475>

Delia Hendrie <http://orcid.org/0000-0001-5022-5281>

REFERENCES

- Stroke Foundation. *Clinical guidelines for stroke management*. Melbourne, Australia, 2019.
- Meyer BC, Raman R, Hemmen T, *et al*. Efficacy of site-independent telemedicine in the STRoKE DOC trial: a randomised, blinded, prospective study. *Lancet Neurol* 2008;7:787–95.
- Wang DZ, Rose JA, Honings DS, *et al*. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. *Stroke* 2000;31:77–81.
- Sairanen T, Soinila S, Nikkanen M, *et al*. Two years of Finnish Telestroke: thrombolysis at spokes equal to that at the hub. *Neurology* 2011;76:1145–52.
- Yaghi S, Harik SI, Hinduja A, *et al*. Post t-PA transfer to hub improves outcome of moderate to severe ischemic stroke patients. *J Telemed Telecare* 2015;21:396–9.
- Barlinn J, Gerber J, Barlinn K, *et al*. Acute endovascular treatment delivery to ischemic stroke patients transferred within a telestroke network: a retrospective observational study. *Int J Stroke* 2017;12:502–9.
- Whetten J, van der Goes DN, Tran H, *et al*. Cost-effectiveness of access to critical cerebral emergency support services (ACCESS): a neuro-emergent telemedicine consultation program. *J Med Econ* 2018;21:398–405.
- Medeiros De Bustos E, Ohannessian R, Bouamra B, *et al*. Télémedecine et accident vasculaire cérébral : « Rôle de la télémedecine dans les accidents vasculaires cérébraux ». *Bulletin de l'Académie Nationale de Médecine* 2020;204:826–38.
- Demaerschalk B, Switzer J, Xie J, *et al*. Cost-utility analysis of hub-and-spoke telestroke networks for the management of acute ischemic stroke from a societal perspective (P05.244). *Neurology* 2012;78:P05.244.
- Nelson RE, Saltzman GM, Skalabrini EJ, *et al*. The cost-effectiveness of telestroke in the treatment of acute ischemic stroke. *Neurology* 2011;77:1590–8.
- Switzer J, Demaerschalk B, Xie J. Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspective. *Circ Cardiovasc Qual Outcomes* 2013;7:8.
- Adams R, Jones A, Lefmann S, *et al*. Utilising a collective case study system theory mixed methods approach: a rural health example. *BMC Med Res Methodol* 2014;14:94.
- Kidholm K, Ekland AG, Jensen LK, *et al*. A model for assessment of telemedicine applications: mast. *Int J Technol Assess Health Care* 2012;28:44–51.
- Castro FG, Kellison JG, Boyd SJ, *et al*. A methodology for conducting integrative mixed methods research and data analyses. *J Mix Methods Res* 2010;4:342–60.
- Andersen KK, Olsen TS, Dehlendorff C, *et al*. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. *Stroke* 2009;40:2068–72.
- Nelson RE, Okon N, Lesko AC, *et al*. The cost-effectiveness of telestroke in the Pacific Northwest region of the USA. *J Telemed Telecare* 2016;22:413–21.
- Kazley AS, Simpson KN, Simpson A, *et al*. Optimizing the economic impact of rtPA use in a stroke belt state: the case of South Carolina. *Am Health Drug Benefits* 2013;6:155.
- Samsa GP, Reutter RA, Parmigiani G, *et al*. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. *J Clin Epidemiol* 1999;52:259–71.
- Glick HA. Sample size and power for cost-effectiveness analysis (part 1). *Pharmacoeconomics* 2011;29:189–98.
- Edney LC, Haji Ali Afzali H, Cheng TC, *et al*. Estimating the reference incremental cost-effectiveness ratio for the Australian health system. *Pharmacoeconomics* 2018;36:239–52.
- Lee AH, Somerford PJ, Yau KKW. Risk factors for ischaemic stroke recurrence after hospitalisation. *Med J Aust* 2004;181:244–6.
- Damschroder LJ, Aron DC, Keith RE, *et al*. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci* 2009;4:50.
- Lu Y. *Using consolidated framework for implementation research (CFIR) to improve information governance (IG) implementation in healthcare*, 2018.
- Finch TL, Mair FS, O'Donnell C, *et al*. From theory to 'measurement' in complex interventions: methodological lessons from the development of an e-health normalisation instrument. *BMC Med Res Methodol* 2012;12:69.
- Strauss A, Corbin J. *Basics of qualitative research*. Sage publications, 1990.